ASCENTAGE PHARMA Files 6-K with Press Release, HKEX Announce

TL;DR

**ASCENTAGE PHARMA just dropped a 6-K with a press release and HKEX announcement, so expect news.**

AI Summary

ASCENTAGE PHARMA GROUP INTERNATIONAL filed a 6-K on March 26, 2026, including a press release and a Hong Kong Stock Exchange announcement, both dated March 25, 2026. This filing, with accession number 0001213900-26-034372, indicates the company is providing updated information to investors, likely related to recent business developments or financial disclosures. For shareholders, this matters because it signals the company is actively communicating important, potentially market-moving news, which could impact the stock's valuation.

Why It Matters

This filing indicates ASCENTAGE PHARMA is providing new, potentially significant information to the market, which could influence investor perception and stock price.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the content of the attached press release and HKEX announcement could contain high-impact news, making the overall risk medium until contents are reviewed.

Analyst Insight

An investor should immediately review the attached EX-99.1 (Press Release) and EX-99.2 (Hong Kong Stock Exchange Announcement) to understand the specific details and implications of the information being disclosed by ASCENTAGE PHARMA GROUP INTERNATIONAL.

Key Players & Entities

• ASCENTAGE PHARMA GROUP INTERNATIONAL (company) — the filer of the 6-K
• 0002023311 (company) — CIK of the filer
• 0001213900-26-034372 (other) — SEC Accession No. for the filing
• March 26, 2026 (date) — the filing date of the 6-K
• March 25, 2026 (date) — date of the press release and Hong Kong Stock Exchange announcement

Forward-Looking Statements

• The content of the attached press release and HKEX announcement will contain significant updates regarding ASCENTAGE PHARMA's drug development or financial performance. (ASCENTAGE PHARMA GROUP INTERNATIONAL) — medium confidence, target: 2026-03-27

FAQ

Filing Documents

• ea0283522-6k_ascentage.htm (6-K) — 13KB
• ea028352201ex99-1.htm (EX-99.1) — 140KB
• ea028352201ex99-2.htm (EX-99.2) — 1338KB
• ea028352201_ex99-2img1.jpg (GRAPHIC) — 45KB
• ea028352201_ex99-2img2.jpg (GRAPHIC) — 46KB
• ea028352201_ex99-2img3.jpg (GRAPHIC) — 47KB
• ea028352201_ex99-2img4.jpg (GRAPHIC) — 51KB
• 0001213900-26-034372.txt ( ) — 1753KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2026 Commission File Number: 002-023311 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F The information in this Report on Form 6-K (this “Report”) of Ascentage Pharma Group International (the “Company”), including Exhibits 99.1 and 99.2 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act. INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K Press Release On March 25, 2026, the Company issued a press release announcing its unaudited financial results for the fourth quarter and year ended December 31, 2025 and a business update. A copy of the press release is furnished as Exhibit 99.1 to this Report. Announcement On March 25, 2026, the Company issued a Hong Kong Stock Exchange announcement entitled, “Announcement of Annual Results For The Year Ended December 31, 2025; and Change of Company Secretary and Authorised Representative”. A copy of the announcement is furnished as Exhibit 99.2 to this Report. 1 INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Press Release dated March 25, 2026 99.2 Hong Kong Stock Exchange Announcement dated March 25, 2026 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: March 26, 2026 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR